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Poster Session I S273Further work is currently ongoing to study the effect of sub-
continental ancestry on HSCT outcomes for fully HLA matched
patient/donor pairs. This work has the potential to demonstrate clin-
ical relevance of ancestry beyond the categories where it is typically
self-identified.
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SIBLING CORD AND BONE MARROW INFUSION TO CURE BETA THALAS-
SAEMIA MAJOR
Raj, R., Munirathnam, D., Khandelwal, V., Sri, K., Kumar, M.,
Lakshmanan, V. Apollo Speciality Hospital, Chennai, Tamilnadu, India
There are 10,000 new births of beta thalassaemia major in India
each year. The burden of long term transfusion and chelation in
such children is huge and themajority of such patients in our country
face early death in their teenage due to cardiac or liver haemosidero-
sis. Private cord blood banks have been operational in India since
2002. We present a series of 8 children with thalassaemia major
who have been cured of their disease by their saviour sibling. All 8
children were transfusion dependent thalassaemia major with age
range 2 years to 9 years. Three children were Lucarelli class I and
the other five were class III. Six children received thiotepa, treosul-
phan and fludarabine conditioning and two had busulphan and cy-
clophosphamide. The cord was thawed and infused first followed
by bone marrow harvested from the sibling. The sibling donors
were between 7 months to 3 years of age. Bone marrow was used
in addition to cord for two reasons – cord nucleated cell count alone
was inadequate in all 8 cases and data was not yet available in our
country regarding post thaw nucleated count from private cord
banks. Total nucleated cell count from the cryopreserved cord
ranged from 0.5 x 106 / kg to 1 x 107 / kg in these eight children
and the CD 34 ranged from 0.18 x 104 / kg to 1.8 x 105 / kg. Bone
marrow harvest yielded 1 to 7 x 106 / kg CD34 count after harvesting
less than 5ml/kg marrow of the recipient body weight. There was on
average 38% cell loss after thawing from different private cord blood
banks in India. All patients engrafted between days 12 to day 17 with
persistent donor chimerism between 90 to 100% after more than
a year follow up. There was no graft versus host disease or cytomeg-
alovirus reactivation in any of these children.
We conclude that the use of cord and bone marrow helps cure
thalassaemia with the benefit of durable engraftment without graft
versus host disease. Cord blood banking should be recommended
by all physicians managing children with thalassaemia. It is an ideal
source of stem cells for transplantation and should be used even if the
cell dose seems suboptimal and balanced with addition of cells from
bone marrow.IMMUNE RECONSTRUCTION188
TIM-3 IS AN INDUCIBLE HUMAN NATURAL KILLER (NK) CELL RECEPTOR
THAT ENHANCES INTERFERON GAMMA PRODUCTION IN RESPONSE TO
GALECTIN-9 (GAL-9)
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Natural killer cells are an attractive option for immunotherapy, as
the adoptive transfer of alloreactive NK cells has demonstrated anti-
leukemia effects in transplant and non-transplant settings. Natural
killer cell function is regulated by the integration of signals received
from activating and inhibitory receptors. Here we show that a novel
immune receptor, Tim-3, is expressed on resting human NK cells
and is upregulated upon activation. The NK92 NK cell line engi-
neered to overexpress Tim-3 showed a marked increase in IFN-g
production in the presence of soluble rhGal-9 or Raji tumor cells en-
gineered to express Gal-9. The Tim-3+ population of low dose IL-
12/IL-18-activated primary NK cells significantly increased IFN-g
production in response to soluble rhGal-9, Gal-9 presented by cell
lines, and primary acute myelogenous leukemia (AML) targets thatendogenously express Gal-9. This effect is highly specific as Tim-3
crosslinking induced extracellular signal-regulated kinase activation,
degradation of the NF-kB inhibitor IkBa, and Tim-3 antibody
blockade significantly decreased IFN-g production. Exposure to
Gal-9 expressing target cells had little effect on CD107a expression.
Reconstituted NK cells obtained from patients after hematopoietic
cell transplant had diminished expression of Tim-3 compared to
paired donors and correlated with a decrease in IFN-g production,
a known defect seen early after transplant. Upon low dose IL-12/
IL-18 activation, Tim-3 expression was rescued in post-transplant
developing NK cells, which correlated with an increase in IFN-g
production. Modeling human NK cell development in vitro, NK
cells derived from umbilical cord blood (UCB) CD34+ progenitor
cells cultured on the murine stromal cell line EL08.1D displayed
lower levels of Tim-3 expression and IFN-g production in the pres-
ence of rhGal-9 and low dose IL-12/IL-18 cytokine priming. Tim-3
overexpressing UCB-derived NK cells activated with low dose
IL-12/IL-18, however, significantly increased IFN-g production in
response to rhGal-9. Application of the Tim-3 blocking antibody
abrogated this effect, supporting the premise that Tim-3 is develop-
mentally regulated in vivo. In conclusion, we show that Tim-3 func-
tions as an activating co-receptor in human NK cells to enhance
IFN-g production. Understanding Tim-3 mechanisms can lead to
strategies to enhance NK cell function after transplantation.
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IMMUNE RECONSTITUTION IN CHILDREN RECEIVING CORD BLOOD
TRANSPLANTATION (CBT) WITHOUT THE USE OF LYMPHOCYTOLYTIC
ANTIBODIES
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Immune reconstitution following CBT can be prolonged and
heighten the risk for infection. In this prospective studywe substituted
fludarabine for a lymphocytolytic antibody such as ATG or Campath
with the intent of accelerating immune reconstitution and reducing
the incidence of viral infections. Fifteen children (median age 12
months,range, 1 mo – 8 yr) with; Primary Immune Deficiency (n 5
5), HLH (n 5 1), alpha mannosidosis (n5 1), Fanconi Anemia (n5
1), Dyskeratosis Congenita (n 5 1), SAA (n 5 1) and acute leukemia
(n 5 5) were treated. Four patients were HLA fully matched and 11
were one HLA antigen mismatched. The median total nucleated
cell dose was 10.2x108 /kg (range, 5.1 x 108 – 25.4 x 108). Ten patients
received myeloablative conditioning consisting of busulfan, cyclo-
phosphamide and fludarabine for their non-malignant conditions
while 5 patients with acute leukemia received cyclophosphamide,
fludarabine and total body irradiation. Patients with chromosomal
breakage/instability syndromes received reduced intensity condition-
ing without serotherapy. The median time to neutrophil and platelet
engraftment was 25d (range, 15d-30d) and 48d (range, 30d-60d), re-
spectively. All patients achieved 100% donor chimerism by day +42.
Median absolute number of CD3+ cells was 394/ul at day 42(range,
79-918) and 638/ul at day 100 (range, 187-1632). Median absolute
number of CD4+ and CD8+ cells was 330/ul (range, 56-826) and
65/ul x 103(range, 13-86) by day 42, respectively.Themedian absolute
B cell numberwas 1098/ul (range, 36-1202) by 6months. In vitro lym-
phocyte proliferative responses to phytoghemagglutinin were
$75,000 cpm 3H-thymidine incorporation in 8/15 patients by day
42 and in all the patients by day 60. Stimulation index in response to
specific antigens (candida/tetanus) was $2 by 6 months post UCBT.
One patient had EBV reactivation which resolved spontaneously
and one patient had CMV reactivation responsive to treatment with
donor derived CTL infusion. No patient developed viral disease.
aGVHD grade II-IV was seen in three patients. No cGvHD has oc-
curred. The 1-year overall survival is 72% [95%CI (41-89%)] with
amedian follow up of 385 days (4d-798d).Hence omitting lymphocy-
tolytic antibodies from conditioning regimens for CBTmay be asso-
ciated with ealier phenotypic and functional engraftment and
immune-reconstitution in the absence of increased risk for significant
GvHD, leading to a high overall survival of pediatric patients after
cord blood transplantation.
